Annemiek Broyl

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. doi request reprint General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma
    Annemiek Broyl
    Erasmus MC, Rotterdam, The Netherlands
    Semin Hematol 49:249-57. 2012
  2. doi request reprint Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
    Annemiek Broyl
    Department of Hematology, Erasmus Medical Center and University, Rotterdam, The Netherlands
    Blood 116:2543-53. 2010
  3. ncbi request reprint Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
    Annemiek Broyl
    Department of Haematology, Erasmus MC, Rotterdam, Netherlands
    Lancet Oncol 11:1057-65. 2010
  4. doi request reprint High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
    Annemiek Broyl
    Department of Hematology, Erasmus MC, Rotterdam, The Netherlands
    Blood 121:624-7. 2013
  5. ncbi request reprint Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial
    Pieter Sonneveld
    Erasmus Medical Center, Rotterdam, The Netherlands
    J Clin Oncol 30:2946-55. 2012
  6. pmc Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy
    Mark van Duin
    Department of Hematology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Haematologica 96:1662-9. 2011

Detail Information

Publications6

  1. doi request reprint General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma
    Annemiek Broyl
    Erasmus MC, Rotterdam, The Netherlands
    Semin Hematol 49:249-57. 2012
    ..Here, we discuss all aspects of bortezomib-induced peripheral neuropathy (BiPN), and elaborate on the mechanisms underlying the development of BiPN...
  2. doi request reprint Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
    Annemiek Broyl
    Department of Hematology, Erasmus Medical Center and University, Rotterdam, The Netherlands
    Blood 116:2543-53. 2010
    ..To conclude, in addition to 7 clusters described in the UAMS classification, we identified 3 novel subsets of multiple myeloma that may represent unique diagnostic entities...
  3. ncbi request reprint Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
    Annemiek Broyl
    Department of Haematology, Erasmus MC, Rotterdam, Netherlands
    Lancet Oncol 11:1057-65. 2010
    ....
  4. doi request reprint High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
    Annemiek Broyl
    Department of Hematology, Erasmus MC, Rotterdam, The Netherlands
    Blood 121:624-7. 2013
    ..trialregister.nl) as NTR213; at the European Union Drug Regulating Authorities Clinical Trials (EudraCT) as 2004-000944-26; and at the International Standard Randomized Controlled Trial Number (ISRCTN) as 64455289...
  5. ncbi request reprint Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial
    Pieter Sonneveld
    Erasmus Medical Center, Rotterdam, The Netherlands
    J Clin Oncol 30:2946-55. 2012
    ..We investigated whether bortezomib during induction and maintenance improves survival in newly diagnosed multiple myeloma (MM)...
  6. pmc Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy
    Mark van Duin
    Department of Hematology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Haematologica 96:1662-9. 2011
    ....